NEW YORK — The National Advertising Division on Tuesday referred advertising claims made by Bremmen Clinical, for its Vysera-CLS weight-loss supplement, to the Federal Trade Commission for further review.
NAD had requested substantiation for certain claims made by Bremmen Clinical for Vysera, including: “As incredible as it sounds, groundbreaking research has just identified a compound that can not only help you lose weight, but can actually reshape your entire body, reducing waist size, hip size, thigh and buttock circumference and … last but not least … cause a significant loss of actual fat mass from all over your body. Has the 'miracle pill' finally arrived?”
However, during the course of its review, NAD learned Bremmen Clinical is associated with Basic Research, a company that has entered into a 20-year consent order with the FTC regarding advertising weight-loss claims for several of its dietary supplements.
NAD procedures provide that NAD may administratively close a proceeding, as it did in this case, when the claims at issues are the subject of federal agency consent decree or order.
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.